These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8358000)

  • 1. Marked overproduction of non-cyclooxygenase derived prostanoids (F2-isoprostanes) in the hepatorenal syndrome.
    Morrow JD; Moore KP; Awad JA; Ravenscraft MD; Marini G; Badr KF; Williams R; Roberts LJ
    J Lipid Mediat; 1993; 6(1-3):417-20. PubMed ID: 8358000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved quantification of 8-epi-prostaglandin F2 alpha and F2-isoprostanes by gas chromatography/triple-stage quadrupole mass spectrometry: partial cyclooxygenase-dependent formation of 8-epi-prostaglandin F2 alpha in humans.
    Schweer H; Watzer B; Seyberth HW; Nüsing RM
    J Mass Spectrom; 1997 Dec; 32(12):1362-70. PubMed ID: 9423285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced lipid peroxidation in hepatic cirrhosis.
    Pratico D; Iuliano L; Basili S; Ferro D; Camastra C; Cordova C; FitzGerald GA; Violi F
    J Investig Med; 1998 Feb; 46(2):51-7. PubMed ID: 9549227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of urinary 8-epi-prostaglandin F2 alpha during cyclo-oxygenase inhibition in rats but not in man.
    Bachi A; Brambilla R; Fanelli R; Bianchi R; Zuccato E; Chiabrando C
    Br J Pharmacol; 1997 Aug; 121(8):1770-4. PubMed ID: 9283716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulatory effect of 8-Epi-PGF2 alpha, an F2-isoprostane, on endothelin-1 release.
    Fukunaga M; Yura T; Badr KF
    J Cardiovasc Pharmacol; 1995; 26 Suppl 3():S51-2. PubMed ID: 8587462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatorenal syndrome.
    Bataller R; Arroyo V; Ginès P; Sort P
    Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles.
    Hoffman SW; Moore S; Ellis EF
    Stroke; 1997 Apr; 28(4):844-9. PubMed ID: 9099206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hepatorenal syndrome].
    Mijac D; Kezić A; Stojimirović B
    Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism.
    Morrow JD; Hill KE; Burk RF; Nammour TM; Badr KF; Roberts LJ
    Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9383-7. PubMed ID: 2123555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man.
    Wang Z; Ciabattoni G; Créminon C; Lawson J; Fitzgerald GA; Patrono C; Maclouf J
    J Pharmacol Exp Ther; 1995 Oct; 275(1):94-100. PubMed ID: 7562601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury.
    Roberts LJ; Morrow JD
    Ann N Y Acad Sci; 1994 Nov; 744():237-42. PubMed ID: 7825845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids.
    Morrow JD; Awad JA; Boss HJ; Blair IA; Roberts LJ
    Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10721-5. PubMed ID: 1438268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatorenal syndrome.
    Gattoni A; Marotta F; Vangieri B; Pisani G; Cristiano F
    Clin Ter; 2004 Sep; 155(9):375-89. PubMed ID: 15700631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: pathogenesis and pathophysiology of hepatorenal syndrome--is there scope for prevention?
    Møller S; Henriksen JH
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():31-41; discussion 42-3. PubMed ID: 15335398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatorenal syndrome: diagnostic accuracy, clinical features, and outcome in a tertiary care center.
    Watt K; Uhanova J; Minuk GY
    Am J Gastroenterol; 2002 Aug; 97(8):2046-50. PubMed ID: 12190175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of hepatorenal syndrome.
    Ginès P
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Dec; 14(6):945-57. PubMed ID: 11139348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphatics.
    Sinzinger H; Oguogho A; Kaliman J
    Lymphology; 1997 Sep; 30(3):155-9. PubMed ID: 9313207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome.
    Moore K; Wendon J; Frazer M; Karani J; Williams R; Badr K
    N Engl J Med; 1992 Dec; 327(25):1774-8. PubMed ID: 1435931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: pharmacological treatment of hepatorenal syndrome.
    Ginès P; Torre A; Terra C; Guevara M
    Aliment Pharmacol Ther; 2004 Sep; 20 Suppl 3():57-62; discussion 63-4. PubMed ID: 15335404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology, clinical features and management of hepatorenal syndrome.
    Garzia P; Ferri GM; Ilardi M; Messina FR; Amoroso A
    Eur Rev Med Pharmacol Sci; 1998; 2(5-6):181-4. PubMed ID: 10710816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.